Discovery and validation of drug targets for tumour angiogenesis.
The formation of blood vessels is a key process in the progression of solid tumours, providing the means for tumour growth and metastasis. A number of drugs are currently being developed to exploit inhibition of angiogenesis in the therapy of cancer. An even greater number of genes that are regulated in models of in vitro angiogenesis have been identified. These genes present potential drug targets for the development of novel, more efficient, drugs that will enable the judicious design of drug cocktails that may be able to account for the many different cancer pathologies and their drug resistance properties. Dealing with the validation of hundreds of potential angiogenesis drug targets requires the utilisation of experimental technology platforms that enable concomitant and dynamic target selection filtering and validation. Such platforms should act as a funnel-like medium-to-low throughput processes that enable the sequential short-listing of hundreds of candidates culminating in the selection of only a small number of well-validated targets that are manageable by drug screening regimes.
Kremmidiotis
Gabriel
G
Lavranos
Tina C
TC
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000592:standards; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000592:standards; D016503:Drug Delivery Systems / Q000379:methods* / Q000592:standards; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000503:physiopathology; D015203:Reproducibility of Results
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents